Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors

被引:48
作者
Foroughi-Nia, Behrouz [1 ,2 ]
Barar, Jaleh [2 ,3 ]
Memar, Mohammad Yousef [4 ]
Aghanejad, Ayuob [2 ]
Davaran, Soudabeh [1 ,2 ]
机构
[1] Tabriz Univ Med Sci, Fac Pharm, Dept Med Chem, Tabriz, Iran
[2] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Biomed Inst, Tabriz, Iran
[3] Tabriz Univ Med Sci, Fac Pharm, Dept Pharmaceut, Tabriz, Iran
[4] Tabriz Univ Med Sci, Infect & Trop Dis Res Ctr, Tabriz, Iran
基金
美国国家科学基金会;
关键词
Tyrosine kinase inhibitor; Theranostic agent; Cancer therapy; Nanotechnology; TARGETED DELIVERY; SYNERGISTIC THERAPY; DRUG-DELIVERY; CO-DELIVERY; ERLOTINIB; SORAFENIB; DOXORUBICIN; CARCINOMA; GEFITINIB; PACLITAXEL;
D O I
10.1016/j.lfs.2021.119642
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Tyrosine kinase inhibitors (TKIs), as an important class of chemotherapeutic drugs, induce apoptosis by altering the path of the cellular signal, resulting in cell death. However, some chemotherapeutic drugs have a limited therapeutic index and are usually destructive as well as unpredictable. In addition, the limitation of early diagnosis and inefficiency of some of the drugs in ordinary treatments lead to disease progression and decreases in the survival of cancer patients. For this purpose, various methods have been proposed, among them, nanomedicine has transpired as a modern approach for the treatment of multiple cancers. Over the last two decades, targeted therapy has been developed for cancer-specific cells/tissues and has rather restricted nonselective toxicities. In vivo and in vitro studies demonstrated nanoparticles (NPs), nano-scale drugs, and nano-carriers alone or in combination with other therapeutic, imaging, and theranostic agents would be applied as an effective approach targeting a diversity of malignant tissue. Therefore, using the latest advances in materials science and biomaterials, biology, it has happened that general diagnosis and treatment can be performed. In this review, we indicated the applications of theranostic nano-polymer and nano-liposome to TKIs delivery.
引用
收藏
页数:11
相关论文
共 50 条
[41]   EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance [J].
Kyle W. Robinson ;
Alan B. Sandler .
Current Oncology Reports, 2013, 15 :396-404
[42]   Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives [J].
Shah, Rashmi R. ;
Morganroth, Joel ;
Shah, Devron R. .
DRUG SAFETY, 2013, 36 (07) :491-503
[43]   Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma [J].
de Rosamel, Laure ;
Blanc, Jean-Frederic .
EXPERT OPINION ON EMERGING DRUGS, 2017, 22 (02) :175-190
[44]   Epidermal growth factor receptor tyrosine kinase inhibitors [J].
M Ranson .
British Journal of Cancer, 2004, 90 :2250-2255
[45]   Factors predicting response to EGFR tyrosine kinase inhibitors [J].
Engelman, JA ;
Jänne, PA .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 26 (03) :314-322
[46]   EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance [J].
Robinson, Kyle W. ;
Sandler, Alan B. .
CURRENT ONCOLOGY REPORTS, 2013, 15 (04) :396-404
[47]   Epidermal growth factor receptor tyrosine kinase inhibitors [J].
Ranson, M .
BRITISH JOURNAL OF CANCER, 2004, 90 (12) :2250-2255
[48]   Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective [J].
Russo, Eleonora ;
Spallarossa, Andrea ;
Tasso, Bruno ;
Villa, Carla ;
Brullo, Chiara .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
[49]   Polymeric Nanoparticles-Tools in a Drug Delivery System in Selected Cancer Therapies [J].
Madej, Marcel ;
Kurowska, Natalia ;
Strzalka-Mrozik, Barbara .
APPLIED SCIENCES-BASEL, 2022, 12 (19)
[50]   Polymeric Nanoparticles Engineered for Optimal Drug Delivery Using Atomistic Computational Simulation [J].
Choodet, Cherdpong ;
Toomjeen, Pakawat ;
Chuaephon, Adulvit ;
Phanchai, Witthawat ;
Srikulwong, Unnop ;
Wiwasuku, Theanchai ;
Puangmali, Theerapong .
ACS APPLIED NANO MATERIALS, 2024, 7 (16) :19698-19708